pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CRL (Complete Response Letter) · news · pharmadog
← back to CRL (Complete Response Letter)
News · CRL (Complete Response Letter)
67
stories
Jul 28, 26
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 27, 26
FDA has recommitted to adcomms—but to what end?
biospace
Jul 23, 26
Update: FDA does not freeze CRL trove as ‘radical transparency’ push hits speedbump
biospace
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 20, 26
FDA’s radical transparency policy for rejections runs into legal uncertainty
biospace
Jul 13, 26
Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
endpoints
Jul 10, 26
FDA returns to releasing pharma rejection letters with 14 new CRLs
endpoints
Jul 9, 26
FDA quietly stops releasing CRLs
endpoints
Jul 2, 26
Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M
endpoints
Jun 30, 26
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
biopharma dive
Jun 30, 26
Unicycive gets second CRL for kidney drug as manufacturing woes continue
endpoints
Jun 17, 26
FDA gives rejected drugs another chance in post-Makary era
endpoints
Jun 11, 26
Camurus’ second CRL for acromegaly drug; Teva details workforce cuts
endpoints
Jun 4, 26
Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug
endpoints
May 8, 26
UT MD Anderson Shares Latest Research Breakthroughs
onclive
May 8, 26
Giants of Cancer Care Announces the 14th Annual Class of Inductees
onclive
May 8, 26
OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates
onclive
May 8, 26
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
onclive
May 8, 26
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
onclive
May 8, 26
Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
onclive
May 7, 26
Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.
onclive
May 7, 26
FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease
onclive
May 7, 26
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
onclive
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
May 7, 26
Reigniting Your Curiosity During Fellowship
onclive
May 6, 26
Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
onclive
May 6, 26
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive
May 6, 26
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
onclive
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
← prev
page 2 of 3
next →